modelBrexucabtageneAutoleucel
Extends from Pharmacolibrary.Drugs.ATC.L.L01XL06.
Information
| name: | BrexucabtageneAutoleucel | |
| ATC code: | L01XL06 | route: | intravenous |
| compartments: | 0 | |
| dosage: | 2000000 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0 | |
| other parameters in model implementation | ||
Brexucabtagene autoleucel is a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, indicated for the treatment of relapsed or refractory mantle cell lymphoma (MCL) in adult patients. It is administered as a single intravenous infusion after lymphodepleting chemotherapy. The drug consists of autologous T cells genetically modified to express a CAR targeting CD19, a protein expressed on B cells. It is currently approved for use.
Pharmacokinetics
Pharmacokinetic data specifically for brexucabtagene autoleucel as a cell therapy product are not reported in standard pharmacokinetic parameters like small molecules, as it is a living cell therapy. Available literature and prescribing information provide data such as CAR-T cell expansion (Cmax, AUC), persistence, and time to peak concentration (tmax), rather than absorption, distribution, or clearance metrics. These parameters are reported for adult patients with relapsed or refractory mantle cell lymphoma.
References
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)